Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET

Contributed by: Business Wire

Logo

Tags

Research

Mental Health

FDA

Clinical Trials

Other Health

Biotechnology

General Health

Pharmaceutical

Health

Science

Compass Pathfinder Limited

More Like This

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD

Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights

Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026

Compass Pathways to Participate in Stifel 2025 Healthcare Conference

Compass Pathways to Present at Stifel 2026 Virtual CNS Forum on March 18, 2026